8 research outputs found
Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs)
No full textTreatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs).
No full textPatientâReported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, PlaceboâControlled, DoubleâBlind and 32âWeek OpenâLabel Study
No full textEffect of Lanreotide Depot/Autogel on Urinary 5âHydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors
No full textNational Working Group Meeting on ALK diagnostics in lung cancer
No full textThe global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors
